vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Fortress Biotech, Inc. (FBIO). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $16.1M, roughly 1.9× Fortress Biotech, Inc.). Fortress Biotech, Inc. runs the higher net margin — -24.5% vs -438.1%, a 413.6% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 6.3%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 11.0%).
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
DOMH vs FBIO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $16.1M |
| Net Profit | $-131.8M | $-3.9M |
| Gross Margin | — | 66.1% |
| Operating Margin | -8.9% | -28.8% |
| Net Margin | -438.1% | -24.5% |
| Revenue YoY | 220.4% | 6.3% |
| Net Profit YoY | -12426.2% | 41.8% |
| EPS (diluted) | $-6.94 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $16.1M | ||
| Q3 25 | $50.8M | $17.6M | ||
| Q2 25 | $34.1M | $16.4M | ||
| Q1 25 | $8.1M | $13.1M | ||
| Q4 24 | $9.4M | $15.1M | ||
| Q3 24 | $4.0M | $14.6M | ||
| Q2 24 | $6.2M | $14.9M | ||
| Q1 24 | $1.4M | $13.0M |
| Q4 25 | $-131.8M | $-3.9M | ||
| Q3 25 | $125.2M | $5.8M | ||
| Q2 25 | $16.6M | $15.5M | ||
| Q1 25 | $-32.5M | $-10.6M | ||
| Q4 24 | $1.1M | $-6.8M | ||
| Q3 24 | $-4.2M | $-12.9M | ||
| Q2 24 | $-6.1M | $-10.9M | ||
| Q1 24 | $-5.4M | $-15.4M |
| Q4 25 | — | 66.1% | ||
| Q3 25 | — | 67.4% | ||
| Q2 25 | — | 69.9% | ||
| Q1 25 | — | 63.5% | ||
| Q4 24 | — | 69.1% | ||
| Q3 24 | — | 69.4% | ||
| Q2 24 | — | 61.6% | ||
| Q1 24 | — | 53.9% |
| Q4 25 | -8.9% | -28.8% | ||
| Q3 25 | -3.1% | -38.6% | ||
| Q2 25 | -57.0% | -222.2% | ||
| Q1 25 | -394.6% | -169.9% | ||
| Q4 24 | 0.4% | -158.3% | ||
| Q3 24 | -79.1% | -151.0% | ||
| Q2 24 | -44.3% | -186.5% | ||
| Q1 24 | -205.2% | -280.6% |
| Q4 25 | -438.1% | -24.5% | ||
| Q3 25 | 246.4% | 33.2% | ||
| Q2 25 | 48.7% | 94.4% | ||
| Q1 25 | -400.5% | -80.6% | ||
| Q4 24 | 11.4% | -44.7% | ||
| Q3 24 | -104.2% | -88.0% | ||
| Q2 24 | -99.1% | -73.5% | ||
| Q1 24 | -398.0% | -118.3% |
| Q4 25 | $-6.94 | $-0.15 | ||
| Q3 25 | $7.27 | $0.11 | ||
| Q2 25 | $1.12 | $0.45 | ||
| Q1 25 | $-3.02 | $-0.48 | ||
| Q4 24 | $0.21 | $-0.16 | ||
| Q3 24 | $-0.67 | $-0.76 | ||
| Q2 24 | $-1.01 | $-0.73 | ||
| Q1 24 | $-0.91 | $-1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $79.4M |
| Total DebtLower is stronger | — | $52.4M |
| Stockholders' EquityBook value | $69.4M | $49.9M |
| Total Assets | $112.9M | $185.5M |
| Debt / EquityLower = less leverage | — | 1.05× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $79.4M | ||
| Q3 25 | $176.2M | $86.2M | ||
| Q2 25 | $28.2M | $74.4M | ||
| Q1 25 | $18.9M | $91.3M | ||
| Q4 24 | $8.2M | $57.3M | ||
| Q3 24 | $7.2M | $58.9M | ||
| Q2 24 | $12.1M | $76.2M | ||
| Q1 24 | $7.1M | $83.8M |
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $47.8M | ||
| Q2 25 | — | $50.0M | ||
| Q1 25 | — | $56.4M | ||
| Q4 24 | — | $58.0M | ||
| Q3 24 | — | $52.5M | ||
| Q2 24 | — | $67.0M | ||
| Q1 24 | — | $61.4M |
| Q4 25 | $69.4M | $49.9M | ||
| Q3 25 | $210.2M | $55.9M | ||
| Q2 25 | $88.6M | $43.9M | ||
| Q1 25 | $42.4M | $22.3M | ||
| Q4 24 | $39.9M | $22.7M | ||
| Q3 24 | $38.3M | $21.2M | ||
| Q2 24 | $42.4M | $17.9M | ||
| Q1 24 | $47.7M | $23.0M |
| Q4 25 | $112.9M | $185.5M | ||
| Q3 25 | $223.4M | $181.4M | ||
| Q2 25 | $109.3M | $159.9M | ||
| Q1 25 | $52.3M | $178.1M | ||
| Q4 24 | $47.1M | $144.2M | ||
| Q3 24 | $43.4M | $127.1M | ||
| Q2 24 | $49.1M | $145.7M | ||
| Q1 24 | $52.2M | $164.6M |
| Q4 25 | — | 1.05× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 2.53× | ||
| Q4 24 | — | 2.55× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | — | 3.75× | ||
| Q1 24 | — | 2.67× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-12.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-12.5M | ||
| Q3 25 | $-4.9M | $-6.1M | ||
| Q2 25 | $-353.0K | $-27.6M | ||
| Q1 25 | $1.2M | $-19.6M | ||
| Q4 24 | $-16.7M | $-12.9M | ||
| Q3 24 | $-4.7M | $-20.1M | ||
| Q2 24 | $1.4M | $-21.8M | ||
| Q1 24 | $-8.6M | $-25.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | -1.04× | ||
| Q2 25 | -0.02× | -1.78× | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
FBIO
Segment breakdown not available.
